CASE Op-Ed – Washington Times: What To Do About Prescription Drug Prices
Matthew Kandrach – President, CASE November 7, 2019 Few policy issues have consumed Washington more over the past year...
White House Withdrawal of Rebate Program Needs Reconsideration
July 11, 2019 Back in January of this year millions cheered President Trump’s plan to finally hold pharmacy benefit managers...
CASE Blog: PBMs – The Bullies of the Healthcare System
March 6, 2019 We continue to support President Trump’s efforts and enthusiasm to bring down healthcare prices. Our suggestion: let’s...
Pharmacy Benefit Managers: Raising Healthcare Costs with no Accountability
2018 has been a watershed year for the effort to reform our nation’s healthcare system and bring down the cost...
Senator Durbin’s Proposal on Drug Advertisements: Simplistic and Wrong
Sen. Richard Durbin (D-IL) introduced an amendment to an appropriations bill this week that would force drug manufacturers to disclose...
CASE Op-Ed – Washington Examiner: A Wishlist for Our Healthcare System Ahead of the Midterms
Matthew Kandrach – President, CASE July 12, 2018 – https://washex.am/2ufXYBS With summer upon us and the midterm elections looming large, Congress...
Pharmacy Benefit Managers: Driving Up Cost of Care with No Accountability
In last week’s Senate Finance Committee hearing on drug pricing, U.S. Secretary of Health and Human Services Alex Azar reiterated the Trump...
The Trump Administration’s Drug Pricing Plan: Three Wishes For Consumers
This week President Trump will unveil his plan to help bring down the cost of prescription drugs, helping fulfill his...
CASE Report: Healthcare Price Index Growth Driven by Hospital Spending
The Health Care Price Index rose by 2.2 percent from March 2017 to March 2018, the largest price increase since...
CASE Op-Ed: PBMs are Pocketing Patient Assistance Money, Increasing Costs for Consumers
Matthew Kandrach – President, CASE April 3rd, 2018 – https://bit.ly/2q4a2UO Pharmacy Benefit Managers (PBMs) — health insurance middle-men wedged between plan...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/